Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19981982 | 0.79 | DPP8 (0.32) | KCNH2 | |
| SCHEMBL27507642 | 0.79 | SLC18A3 (0.33) | SLC18A3 | |
| SCHEMBL19981797 | 0.79 | SIGMAR1 (0.41) | — | |
| SCHEMBL19972739 | 0.79 | SIGMAR1 (0.41) | — | |
| SCHEMBL21294392 | 0.79 | SIGMAR1 (0.41) | — | |
| SCHEMBL19981954 | 0.76 | TRPV3 (0.31) | SLC6A3KCNH2 | |
| SCHEMBL903876 | 0.76 | DPP4 (0.38) | SLC6A3KCNH2 | |
| SCHEMBL19981629 | 0.74 | KCNH2 (0.36) | SLC6A3KCNH2 | |
| SCHEMBL19981999 | 0.74 | L3MBTL3 (0.32) | — | |
| SCHEMBL24109429 | 0.73 | KMT2A (0.42) | KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11292783-B2 | Substituted 1,2,3,4-tetrahydroisoquinolines as kappa opioid antagonists | RESEARCH TRIANGLE INSTITUTE (NC) | 2022-04-05 | — | — | US | disclosed |
| EP-3512832-B1 | TETRAHYDROISOQUINOLINE KAPPA OPIOID ANTAGONISTS | RES TRIANGLE INST (US) | 2021-05-19 | — | — | EP | disclosed |
| US-20190263781-A1 | Tetrahydroisoquinoline Kappa Opioid Antagonists | RESEARCH TRIANGLE INSTITUTE (US) | 2019-08-29 | — | — | US | disclosed |
| WO-2018053222-A1 | TETRAHYDROISOQUINOLINE KAPPA OPIOID ANTAGONISTS | RESEARCH TRAINGLE INSTITUTE (US) | 2018-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11292783-B2 | Substituted 1,2,3,4-tetrahydroisoquinolines as kappa opioid antagonists | OPRK1, OPRD1, OPRM1 | SLC18A3 224/4885SLC6A3 30/4885KCNH2 589/4885 |
| US-20190263781-A1 | Tetrahydroisoquinoline Kappa Opioid Antagonists | OPRK1, OPRD1, OPRM1 | SLC18A3 180/4885SLC6A3 53/4885KCNH2 633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.